Section 130a (8) SGB V enables health insurance funds (KK) and pharmaceutical companies to conclude framework discount agreements for the medicinal products to be dispensed at the expense of the statutory KK. GWQ acts as a company for profitability and quality at KK in accordance with § 130a para. 8 p. 5 SGB V for its shareholder and customer funds. With regard to the relevant legal regulations for the award of public contracts, a regular process of active ingredient-related, formal award procedures in accordance with the regulations of Part 4 of the GWB takes place by GWQ ServicePlus AG. Until the entry into force of new drug discount agreements, GWQ would like to conclude drug discount agreements with all interested pharmaceutical companies as part of the open-house procedure for preparations with the above-mentioned active ingredient. The earliest start date of the contract is 01.10.2023.

GWQ ServicePlus AG intends to conclude non-exclusive discount agreements in accordance with Section 130a (8) SGB V in addition to the above-mentioned active ingredient with a contract start on 01.10.2023. All interested companies can join this contract at any time during the term of the contract under the same conditions (approval model). The GWQ assumes that this procedure does not fall within the scope of antitrust procurement law due to a lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. The contract documents, the participating health insurance companies and their sales as well as the dates for the notification of the contract can be viewed and downloaded on the procurement portal of GWQ ServicePlus AG under http://vergabeportal.gwq-serviceplus.de. Until the start of exclusive contracts, this transitional agreement is open to all market participants for accession. Upon receipt of the signed contracts / declaration and evidence by 10.09.2023, a first notification can be realized on 01.10.2023.

The following documents must be submitted:

- signed contract in duplicate,

— proof of drug approval by means of an extract from the public part of the AMICE database,

- signed self-declaration (Annex 3),

— list of PZNs covered by the contract (Appendix 2),

— Declaration on Council Regulation (EU) 2022/576 of 8 April 2022 amending Regulation (EU) No 833/2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine (Annex 5)